http://www.theamateurfinancier.com/blog/five-investing-cliches/ Thoughts on Money, Investing and Life Wed, 08 Feb 2012 09:26:51 +0000 hourly 1 http://wordpress.org/?v=3.2.1 http://www.theamateurfinancier.com/blog/five-investing-cliches/#comment-307 Roger Fri, 11 Sep 2009 08:23:32 +0000 http://www.theamateurfinancier.com/blog/?p=428#comment-307 I can't say too much about that particular stock, but yes, small cap stocks in general tend to out-perform more established companies. After all, you can only rise to be one of the biggest names in your field once. A healthy dose of small caps in your portfolio is definitely a fine recommendation. I can’t say too much about that particular stock, but yes, small cap stocks in general tend to out-perform more established companies. After all, you can only rise to be one of the biggest names in your field once. A healthy dose of small caps in your portfolio is definitely a fine recommendation.

]]> http://www.theamateurfinancier.com/blog/five-investing-cliches/#comment-304 mlgreen8753 Wed, 09 Sep 2009 07:27:11 +0000 http://www.theamateurfinancier.com/blog/?p=428#comment-304 Great advice. For stock investors, they should consider investing in small cap stocks in ground level opportunities. I heard about a company called Mentor Capital with a 20% stake in a biotech company that has promising new breast cancer clinical trials underway. Right now Mentor Capital stock is only $2.65, but can shoot up when this new treatment hits the market and the medical industry becomes aware of it. According to the article I read on <a href="http://www.breastcancerinvesting.com" rel="nofollow">Breast Cancer Investing</a>, buying Mentor Capital's common stock at its current price of $2.65/share is like a risk-mitigated call option which could pay off exponentially in terms of stock price gains. Great advice. For stock investors, they should consider investing in small cap stocks in ground level opportunities. I heard about a company called Mentor Capital with a 20% stake in a biotech company that has promising new breast cancer clinical trials underway. Right now Mentor Capital stock is only $2.65, but can shoot up when this new treatment hits the market and the medical industry becomes aware of it. According to the article I read on Breast Cancer Investing, buying Mentor Capital’s common stock at its current price of $2.65/share is like a risk-mitigated call option which could pay off exponentially in terms of stock price gains.

]]>